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BACKGROUND: Cancerous stem-like cells (CSCs) have been implicated as cancer-initiating cells in a range of malignant tumours.
Diverse genetic programs regulate CSC behaviours, and CSCs from glioblastoma patients are qualitatively distinct from each other.
The intrinsic connection between the presence of CSCs and malignancy is unclear. We set out to test whether tumour stem-like cells
can be identified from benign tumours.
METHODS: Tumour sphere cultures were derived from hormone-positive and -negative pituitary adenomas. Characterisation of
tumour stem-like cells in vitro was performed using self-renewal assays, stem cell-associated marker expression analysis, differentiation,
and stimulated hormone production assays. The tumour-initiating capability of these tumour stem-like cells was tested in serial brain
tumour transplantation experiments using SCID mice.
RESULTS: In this study, we isolated sphere-forming, self-renewable, and multipotent stem-like cells from pituitary adenomas, which are
benign tumours. We found that pituitary adenoma stem-like cells (PASCs), compared with their differentiated daughter cells,
expressed increased levels of stem cell-associated gene products, antiapoptotic proteins, and pituitary progenitor cell markers. Similar
to CSCs isolated from glioblastomas, PASCs are more resistant to chemotherapeutics than their differentiated daughter cells.
Furthermore, differentiated PASCs responded to stimulation with hypothalamic hormones and produced corresponding pituitary
hormones that are reflective of the phenotypes of the primary pituitary tumours. Finally, we demonstrated that PASCs are pituitary
tumour-initiating cells in serial transplantation animal experiments.
CONCLUSION: This study for the first time indicates that stem-like cells are present in benign tumours. The conclusions from this study
may have applications to understanding pituitary tumour biology and therapies, as well as implications for the notion of tumour-
initiating cells in general.
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Pituitary adenomas are benign brain tumours, but they can cause
significant morbidity due to overexpression of pituitary hormones
(Levy, 2004) or neurological symptoms such as visual loss and
headache (Greenman and Melmed, 1996; Melmed, 2003). Pituitary
adenomas account for about 10% of diagnosed intracranial
neoplasms, typically during early adulthood, yet they are found
in 6–24% of adult autopsies (Laws and Jane, 2001). The
classification of these tumours is usually based on the types of
pituitary hormones they produce, such as prolactin (PRL), growth
hormone (GH), adrenocorticotropic hormone (ACTH), luteinising
hormone (LH), follicle-stimulating hormone (FSH), thyroid-
stimulating hormone (TSH), and others (Levy, 2004). Prolactinomas
are the most common type; they cause amenorrhoea, galactor-
rhoea, and infertility in women and hypogonadism in men.
Somatotrophic adenomas secrete an excess of GH, and cause
gigantism in children and acromegaly in adults. ACTH-secreting
adenomas produce Cushing’s disease, whereas gonadrotophic
(secreting LH and FSH) and thyrotropic adenomas are rare,
with the latter causing hyperthyroidism (Levy, 2004). Some
pituitary adenomas does not secrete hormones and they are
classified as null-cell adenomas, with their diagnosis based on
visual difficulties arising from the compression of the optic nerve
(Greenman and Melmed, 1996; Melmed, 2003). Pituitary adenomas
are also classified based on the size of the tumours: macro-
adenomas are greater than 10mm in diameter and microadenomas
have a diameter of less than 10mm (Shomali and Katznelson,
2002).
Important insights into pituitary adenoma tumorigenesis may
come from studies of pituitary development and cell differentiation.
Pituitary embryogensis is orchestrated by a combination of
intrinsic and extrinsic signals including basic fibroblast growth
factors (bFGF), Wnt, sonic hedgehog, and Notch signals (Scully
and Rosenfeld, 2002; Heaney and Melmed, 2004; Zhu et al, 2007).
Pituitary stem cells may also exist in adult tissues. It had been
reported that a side population from mouse anterior pituitary is
enriched in stem-like cells that express stem/progenitor cell
markers, but not differentiated cell markers, and can grow in
floating spheres in culture (Chen et al, 2005). The side population
also contains some folliculostellate cells (FSCs), the bFGF-
producing stem-like cells. However, nestin-positive cells isolated
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sfrom rat pituitary displayed features of sphere forming, motility,
and proliferation, but are distinct from FSCs (Krylyshkina et al,
2005). The identification of adult pituitary stem cells remains
unclear.
Recent discoveries of cancer stem-like cells (CSCs) as cancer-
initiating cells in malignant cancers, such as gliobastomas (Yuan
et al, 2004; Xu et al, 2008), led to other important questions. Is the
presence of CSCs correlated to malignancy? Do stem-like cells exist
in benign tumours, such as pituitary adenomas? Targeted
expression of human pituitary tumour-transforming gene in
mouse pituitary stem/progenitor cells led to plurihormonal
hyperplasia and adenomas (Abbud et al, 2005), suggesting possibly
a transformed stem cell origin in the tumours. In addition, an
FSC-like cell line was developed from a pituitary adenoma (Danila
et al, 2000). However, whether these cells share stem-like cell
characteristics, and whether these cells can initiate pituitary
adenomas in vivo remains unknown.
In this study, we report the isolation of cloned single cells from
both hormone-producing and hormone-null pituitary adenomas
with the ability to self-renew in sphere culture. These pituitary
adenoma-derived stem-like cells (PASCs) express a range of stem
cell-associated markers and lineage-specific stem/progenitor cell
markers. When differentiated, these cells downregulate stem cell-
associated genes and produce multiple pituitary hormones in
response to hypothalamic hormone stimulation. Finally, when
transplanted into NOD/SCID mice, these sphere-forming cells
generate intracranial tumours that can be serially transplanted to
recapitulate the human tumour.
MATERIALS AND METHODS
Primary culture of pituitary tumour stem-like cells
Tumour stem-like neurospheres were prepared as reported
previously (Yuan et al, 2004). Briefly, tumour samples from eight
pituitary adenoma patients were collected within 30min after the
surgical resection as approved by the Institutional Review Board at
Cedars-Sinai Medical Center. Tissues were washed three times in
PBS 1  and dissected in a dissection medium containing catalase,
deferoxamine, N-acetyl cysteine, and superoxide dismutase. After
digestion in trypsin for 10min at 371C, tumour tissues were
triturated by passing them in a tissue sieve and after recovering the
cells by passing in a 70mm cell strainer. Cells were then plated
at the density of 1 10e5 cells per ml in a medium
containing DMEM/F12 (1:1; Gibco, Carlsbad, CA, USA), B27 1 
(Gibco), penicillin/streptomycin (200Uml
 1; Gibco), fungizone
(250ngml
 1), EGF (20ngml
 1; Peprotech, Rocky Hill, NJ, USA),
and bFGF (20ngml
 1; Peprotech). For the differentiation of pituitary
tumour stem cells, single-cell suspensions were switched to the
differentiation culture medium (DMEM/F12 medium with 2mM
glutamine, 15% horse serum, and 2.5% fetal bovine serum). After
the pituitary tumour cells attached to the culture dish, these cells
were allowed to grow in the differentiation medium for 7–10 days.
Subsphere formation assays
Subsphere formation assays were performed in 96-well culture
plates as described before (Yuan et al, 2004). Briefly, the spheres
were mechanically dissociated into single cells and diluted into
culture medium. The suspended cells were seeded into 96-well
plates with the dilution that would result in one cell per well. The
single–cell-containing wells were identified by checking the
culture wells 2h after the cell-seeding process. After 2 weeks of
culture with the medium refreshed every 3 days, the culture wells
were observed and the subsphere containing wells were counted.
This subsphere assay was done with different passages of the
sphere cells and experiments were repeated once.
Immunofluorescence staining of tumour cell spheres and
differentiated daughter cells
Tumour cell spheres were harvested and whole spheres were fixed in
4% paraformaldehyde and stained with antibodies against nestin
( 1 : 1 0 0 ;C h e m i c o n ,T e m e c u l a ,C A ,U S A ) ,C D 1 3 3( 1 : 2 0 0 ;A b c a m ,
Cambridge, MA, USA), and GH (1:2000; Chemicon). For staining of
differentiated cells, cells were fixed in 4% paraformaldehyde, followed
by several washing with PBS and permeabilised in 0.1% Triton X-100.
After blocking with 10% goat serum in PBS, cells were then incubated
with primary antibodies: GFAP (1:200; Dako, Carpinteria, CA, USA),
b-tubulin III (1:400; Covance, Berkeley, CA, USA), and S100 (1:200;
Chemicon). After incubation with FITC or Texas Red-conjugated
secondary antibodies (1:300; Jackson ImmunoResearch, West Grove,
PA, USA), slides were countersta i n e dw i t ham o u n t i n gm e d i u m
containing DAPI (Vector Laboratories, Burlingame, CA, USA) before
examination by fluorescence microscopy.
RNA isolation and cDNA synthesis
Total RNA was extracted from fresh tumour tissue, PASCs, and their
daughter cells using an RNA4PCR kit (Amibion, Austin, TX, USA)
according to the manufacturer’s protocol. For cDNA synthesis, 1mg
total RNA was reverse transcribed into cDNA using Oligo dT primer
and iScript cDNA synthesis kit reverse transcriptase. cDNA was
stored at  201C for subsequent PCR analysis.
Real-time quantitative RT-PCR
Gene expression was quantified by real-time quantitative RT-PCR
using QuantiTect SYRB Green dye (Qiagen, Valencia, CA, USA).
DNA amplification was carried out using Icycler (Bio-Rad,
Hercules, CA, USA). All the primer sets were provided by Qiagen
as shown in Supplementary Table 1. The relative quantities of
target gene mRNA against an internal control, GAPDH, was
calculated using a DCT method and an amplification plot with
fluorescence signal vs cycle number was drawn. The difference
(DCT) between the mean values in the duplicated samples of target
genes and those of GAPDH were calculated and the relative
quantified value (RQV) was expressed as 2 DCT.
The relative expression of each gene presented in each clone was
compared between PASC and differentiated cells.
Chemotherapeutic resistance analysis
Tumour stem-like cells and adherent daughter cells were also
tested for resistance to chemotherapeutic treatment. Cells were
treated with 50mM carboplatin and 12.5mM VP16 for 48h and the
toxicity was assessed by WST-1 proliferation assay (Roche,
Indianapolis, IN, USA).
Stimulated hormone production
Pituitary hormone production by PASC1, PASC2, and their
differentiated daughter cells were determined using ELISA. Cells
were cultured with or without 1 10
 7 M GH-releasing factor
(GHRF), 2 10
 7 M PRL-releasing peptide (PRP), 1 10
 7 M LH-
releasing hormone (LHRH), 1 10
 7 M thyrotropin-releasing
hormone (TRH), and 1 10
 7 M corticotropin-releasing hormone
(CRH) for 24h. The secreted hormones (GH, PRL, LH, TSH, FSH,
and ACTH) in the conditioned media were determined using
ELISA kits (Anogen, Mississauga, Ontario, Canada). The results
are the average±standard deviation of three independent experi-
ments. For immunofluorescence staining of human GH and FSH
expressed in differentiated PASCs, cells were fixed and stained
with antibodies specific to human hormones at 24h after
hypothalamic hormone stimulation. Nuclei were detected with
DAPI staining.
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NOD/SCID mice (6–8 weeks old; Jackson Laboratory, Bar Harbor,
Maine, USA) were anesthetised with i.p. ketamine and medetomi-
dine, and stereotactically implanted with pituitary adenoma sphere
cells (PASC1–4 and human glioblastoma U87 cells, 10000 per
mouse) in the right forebrains. At 3 and 6 months after
implantation, two animals from each of the above implanted mice
were killed, followed by intracardiac perfusion–fixation with 4%
paraformaldehyde. Immunostaining of the brain sections was
performed with human-specific antibody against human cell nuclei
(1:100; Chemicon) and also with antibody against human-specific
growth hormone (1:2000; Chemicon). Alternatively, the implanted
mice were killed at 12 weeks. The mouse forebrains around the
implantation site were harvested under a dissection microscope
and the dissected samples were homogenised. A human growth
hormone-specific ELISA kit was used to detect the levels of human
GH in the homogenised tissues. For serial transplantation, fresh
human tumour cells harvested from the brains of mice that
survived 6 months after implantation were cultured under the
same conditions as described above and expanded as spheres. The
same number of pituitary adenoma cells was implanted into mice
following the same procedure as described above. At 3 months
after implantation, animals were killed and the brains were subject
to histological analysis for secondary tumour formation. All
animals used were treated in strict accordance with the Institu-
tional Animal Care and Use Committee guidelines enforced at the
Cedars-Sinai Medical Center.
RESULTS
Isolation of PASCs and their self-renewal and multipotent
capacity
Previously, we had isolated brain tumour stem-like cells
from malignant brain tumours, namely, glioblastoma multiforme
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Figure 1 Pituitary adenoma stem-like cells form self-renewable spheres in culture. (A) Histological characterisation of a human pituitary somatotroph
adenoma: (a) Hematoxylin and eosin; (b) human GH; (c) human PRL; and (d) Ki67 staining. Scale bar, 10mm. (B) Tumour cells from one growth hormone-
positive (PA1; a, c, e) and one null-cell (PA2; b, d, f) pituitary adenomas were cultured in serum-free neural stem cell medium. Initially tumour cells grow as
monolayers with epithelial cell morphology (a, b). In a week, tumour cells form spheres on top of the monolayers (c, d). Both tumour stem-like cells are
continuously propagated as free-floating spheres in culture (e, f). (C) Single tumour stem-like cells were cloned from both growth hormone-positive
(PASC1) and null cell (PASC2) tumour spheres. There was no significant change in subsphere-forming efficiency of both PASC1 (open bar) and PASC2
(closed bars).
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tumour-initiating cells exist in benign tumours or specifically, in
pituitary adenomas, we cultured tumour cells from a number of
clinical specimens of pituitary tumours. Detailed characterisation
and functional studies were focused on tumour cells from one GH-
positive somatotroph tumour and one hormone-negative null-cell
macroadenoma. The GH-positive somatotroph tumour was
positive in human GH staining and cell proliferation antigen
staining, with moderate PRL staining (Figure 1A). Under the
culture conditions identical to those for neural stem cells, spheres
resembling typical neurospheres readily formed on top of the
monolayers of both cells (Figure 1B a–d). The spheres could be
propagated and continuously cultured in a free-floating form
(Figure 1B e and f). Single cells were cloned from spheres for each
tumour and expanded for subsequent studies. To assess their self-
renewal capacity, subsphere-forming assays were performed for
both cells. At passages 3 and 15, both cells displayed consistent
subsphere-forming efficiency (Figure 1C). Therefore, both tumour
cells forms self-renewable spheres in culture.
To test whether these sphere-forming tumour cells express cell
markers, which are shared by neural stem cells and glioblastoma
stem-like cells, both tumour cells were stained with immuno-
fluorescence using antibodies against nestin and CD133. As shown
in Figure 2A and B, both tumour cells express neural stem cell
markers nestin and CD133. In addition, GH-positive staining was
found only in dispersed somatotroph tumour cells, but not in
sphere-forming cells (Figure 2A g–i). Thus, sphere-forming
pituitary tumour cells express stem/progenitor cell markers, but
not differentiated cell markers. Next, sphere-forming tumours
were cultured under differentiation conditions for 1 week and
analysed for the expression of lineage-specific markers. Upon
differentiation, these cells acquired an epithelial morphology
resembling original pituitary adenoma cells. Differentiated cells
were found to express neural-specific b-tubulin III, astroglial
protein GFAP, and brain-specific protein S-100 (Figure 2C),
suggesting that these cells had multipotent differentiation capacity.
Therefore, we have isolated sphere-forming, self-renewable, and
multipotent pituitary adenoma stem-like cells (PASCs) from both
GH-positive somatotroph tumours and null-cell tumours, PASC1
and PASC2, respectively.
Expression of stem cell-associated genes by PASCs and
chemosensitivity analysis
To further characterise these benign tumour-derived stem-like
cells, we determined the gene expression levels of a series of stem-
cell-associated genes in both PASC1 and their daughter cells.
CD90, OCT4, Musashi-1 (MSI), NOTCH4, JAG2, and DLL-1 are
typically expressed in embryonic or adult stem cells (Kaneko et al,
2000; Kabos et al, 2002; Nagato et al, 2005). We found that
expression levels of these stem cell-associated genes were higher in
PASC1 than in its differentiated daughter cells (Figure 3A a). Stem
cells are generally known to preferentially express antiapoptotic
genes, such as BCL-2, cIAP1, NAIP, and XIAP (Jin et al, 2008). It
was determined that the expression levels of these antiapoptotic
genes in PASC1 were one- to sixfolds higher than those in its
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Figure 2 Pituitary adenoma cells express neural stem cell markers and possess multipotential differentiation capability. (A and B) Immunofluorescence
staining of pituitary tumour spheres from PASC1 (A) and PASC2 (B) with antibodies against nestin (green; A-a and B-a) and CD133 (red; A-d and B-d).
Nuclei were detected with DAPI staining (blue; A-b, e, h and B-b, e). Overlaps of antibody and nuclei staining were shown (A-c, f, i and B-c, f). (C) Single-
cell suspension from tumour cell spheres was plated and grown in differentiation medium for 7–10 days. Immunofluorescence staining of differentiated
pituitary adenoma stem-like cells (PASC1) was performed with antibodies against b-tubulin III (a), GFAP (c), and S100 (e). Nuclei were revealed with DAPI
staining (b, d, f).
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the expression levels of multiple drug resistance related genes,
such as BCRP1, MDR1, MRP1, and MRP3 (Donnenberg and
Donnenberg, 2005; Abbott, 2006), between PASC1 and the
daughter cells (data not shown). Next, we determined gene
expression levels of some genes important for pituitary develop-
ment, including Pit-1, aGSU, GATA2, and other genes. Pit-1 is a
transcription factor that regulates expression of GH and PRL. Pit-1
is expressed in progenitor cells in developing pituitary glands and
its expression precedes GH messenger RNA expression in fetal
pituitary glands (Scully and Rosenfeld, 2002). GATA2 is a zinc
finger transcription factor necessary for differentiation and
determination of gonadotrophs and thyrotrophs (Scully and
Rosenfeld, 2002). The expression of Pit-1 is over fourfold higher
in PASC1 than in the daughter cells (Figure 3B). The expression of
aGSU is also increased in PASC1 (Figure 3B), whereas GATA2 is
similarly expressed in both PASC1 and the daughter cells. No
detectable mRNA expression of LH, FSH, TSH, ACTH, NeuroD1
(Oyama et al, 2001), Tpit, SF-1 (Barnhart and Mellon, 1994), and
PROP1 was found in either PASC1 or the daughter cells (data not
shown).
We reported in a previous study that glioblastoma stem-like
cells are characterised by their high resistance to chemotherapeutic
agents, including carboplatin, etoposide (VP16), and other drugs
(Liu et al, 2006). To test whether PASC1 shares this property with
malignant tumour stem-like cells, we treated PASC1 and its
daughter cells with carboplatin and VP16 and performed toxicity
assays. As shown in Figure 3C, PASC1 manifested significantly
higher resistance than the daughter cells to both chemotherapeutic
treatments. Therefore, PASCs express a broad range of stem
cell-associated genes and possess chemotherapeutic resistance
property.
PASCs are responsive to hypothalamic hormones and can
produce multiple pituitary hormones
One hallmark of differentiated pituitary cells is their responsiveness
to hypothalamic hormones and the ensuing production of
pituitary hormones. To investigate whether PASCs can be
differentiated into hormone-producing cells, both PASC1 and
PASC2 were cultured in a differentiation medium for 2 weeks,
followed by stimulation of hypothalamic hormones, including
GHRF, PRP, LHRH, TRH, and CRH. The conditioned media from
PASC1, PASC2, and their respective daughter cells were analysed
using ELISA assays for the presence of main pituitary hormones,
including GH, PRL, FSH, LH, TSH, and ACTH. As shown in
Figure 4A, only cells differentiated from PASC1 responded to
GHRF and LHRH and produced GH, FSH, and LH (Figure 4A
a,c,e). Interestingly, both PASC1 and its daughter cells responded
to PRP and TRH and produced PRL and TSH (Figure 4A b,d).
Neither PASC1 nor its daughter cells produced ACTH regardless of
stimulation (Figure 4A f). In contrast, cells differentiated from
macroadenoma-derived PASC2 manifested different responsive-
ness to hypothalamic hormone stimulation and hormone
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Figure 3 Pituitary adenoma stem-like cells preferentially express stem cell-associated genes and display drug resistance. (A) Ratios of expression levels of
stem cell-associated genes (a) and antiapoptotic genes (b) in tumour stem-like cells relative to adherent daughter cells. Total RNA was isolated from tumour
stem-like cells and their differentiated daughter cells. The mRNA expression levels of each gene were quantified using real-time PCR methods and the ratios
were calculated using normalised expression data. (B) Ratios of expression levels of pituitary stem cell-associated genes (aGSU and Pit1) in tumour stem-like
cells relative to adherent daughter cells. (C) Chemosensitivity in tumour stem-like cells and their daughter cells. Tumour stem-like cells and daughter cells
were treated with carboplatin and VP16 at the indicated concentrations for 48h. Surviving cells were quantified using WST-1 assays.
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produced GH, PRL, TSH, or ACTH in the presence or absence of
hypothalamic hormone stimulation. However, only undifferentiated
PASC2 produced LH, and only differentiated PASC2 produced FSH,
in response to LHRH stimulation (Supplementary Figure 1).
Therefore, PASCs can be differentiated into functional, hormone-
producing cells that respond to hypothalamic hormone stimulation,
and their distinct hormone-producing properties reflected the
characterisation of the corresponding primary pituitary adenomas.
PASCs initiated pituitary tumours that are serially
transplantable
We finally studied whether these PASCs are the pituitary tumour-
initiating cells. To test whether the PASCs have the ability to form
new tumours in vivo,P A S C s( 1  10
4 cells per mouse), their
daughter cells (1 10
5 cells per mouse), or glioblastoma cells
(1 10
4 cells per mouse, as control) were stereotactically implanted
into the right hemisphere of NOD/SCID mice. At 3 months after the
intracranial implantation, human-specific cells were identified by
immunostaining in the brains of mice that received PASC
implantation. However, there was no human-specific cell found
within the brains of mice that received the daughter cell
implantation (Figure 5A; only results from PASC1 are shown).
At 6 months after the intracranial implantation, larger areas of
human-specific cell masses were identified in the brains of mice that
received PASC implantation compared with that of 3 months after
the intracranial tumour spheres implantation (Figure 5A). There was
no human-specific cell found within the brains of mice that received
daughter cells at 6 month. Furthermore, only brain tumours from
PASC1 cells were GH-positive, as indicated by immunostaining of
brain sections with a human GH-specific antibody (Figure 5A).
Histological staining indicated that PASC1 tumours indeed
expressed human GH, as well as moderate human PRL, whereas
only a minority of tumour cells were proliferative based on Ki67
staining (Figure 5B), similar to the histology and hormone
production features of the primary human tumours (see Figure 1A).
To investigate whether the new tumours initiated from PASCs were
serially transplantable, the PASC-generated tumour masses within the
brain were harvested at 6 months after the intracranial implanta-
tion. The harvested tissues were primarily cultured under the same
conditions as those used for the isolation of PASCs. Sphere-
forming cells were identifiable in the culture and the spheres can
be propagated as free-floating spheres in stem cell culture medium.
These sphere cells were retransplanted again into the brains of
NOD/SCID mice (1 10
4 cells per mouse). At 3 months post-
transplantation, the mice were killed and the brain tissues were
processed for human-specific cell identification. All three mice
with the transplantation were found to contain cell masses that are
positive for human-specific nuclei staining, and some cells within
the masses were human GH-positive as well (Supplementary
Figure 2), suggesting that serially transplanted brain tumours
maintain the hormone production property of the primary human
tumours and the first round xenografts (see Figure 5A).
To further test whether these PASC cell-initiated brain tumours
indeed share the property of the primary pituitary tumours for
hormone production, tumours in the mouse forebrains at 12 weeks
after implantation were harvested under a dissection microscope.
The dissected samples were homogenised and the tissue extract
was analysed using a human GH-specific ELISA kit. Significant
amount of human GH was detected only in the samples from
tumours derived from PASC1, but not from tumours from
differentiated PASC1, PASC2, or glioblastoma cells (Figure 5C).
Therefore, PASCs can initiate pituitary tumours that recapitulate
the phenotypes of human primary tumours, and PASCs are
pituitary adenoma-initiating cells.
DISCUSSION
Cancerous stem-like cells have been implicated as cancer-initiating
cells in a range of malignant tumours (Lessard and Sauvageau,
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Figure 4 Pituitary adenoma stem-like cells can differentiate into hormone-producing cells. (A) Pituitary hormone production by differentiated PASC1 in
response to corresponding hypothalamic hormones. PASC1 (open bars) or its differentiated daughter cells (closed bars) were cultured with or without
1 10
 7 M GH-releasing factor (GHRF; a), 2 10
 7 M PRL-releasing peptide (PRP; b), 1 10
 7 M LH-releasing hormone (LHRH; c and e), 1 10
 7 M
thyrotropin-releasing hormone (TRH; d), and 1 10
 7 M corticotropin-releasing hormone (CRH; f) for 24h. The secreted hormones (GH, PRL, LH, TSH,
FSH, and ACTH) in the conditioned media were determined using ELISA kits (Anogen). **Po0.01. (B) Immunofluorescence staining of GH (a) and FSH (b)
expressed in differentiated PASC1 after hypothalamic hormone stimulation. Nuclei were detected with DAPI staining.
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s2003; Singh et al, 2004; Yuan et al, 2004; Bao et al, 2006; O’Brien
et al, 2007; Ricci-Vitiani et al, 2007; Malanchi et al, 2008; Xu et al,
2008). Whether there are any stem-like tumour-initiating cells in
benign tumours is unclear. In this study, we isolated sphere-
forming, self-renewable, and multipotent stem-like cells from
pituitary adenomas, typically benign tumours. We found that
PASCs, compared with their differentiated daughter cells,
expressed increased levels of stem cell-associated gene products,
antiapoptotic proteins, as well as developing pituitary progenitor
cell markers. Similar to cancer stem cells isolated from glioblas-
tomas, PASCs are more resistant to chemotherapeutics than their
differentiated daughter cells. Furthermore, differentiated PASCs
responded to stimulation with hypothalamic hormones and
produced corresponding pituitary hormones that are reflective of
the phenotypes of the primary pituitary tumours. Finally, we
demonstrated that PASCs are pituitary tumour-initiating cells in
serial transplantation animal experiments.
The cancer stem cell theory is currently at the centre of broad
and extensive investigations with both supporting and qualifying
evidences. Recent identification of CSCs from gliomas (Singh et al,
2004; Yuan et al, 2004; Lee et al, 2006), prostate cancers (Collins
et al, 2005), colon cancers (O’Brien et al, 2007; Ricci-Vitiani et al,
2007), and breast cancers (Yu et al, 2007) suggested that CSCs as
cancer-initiating cells may be a general theme in human cancers.
Furthermore, it is proposed that CSCs may be responsible for
cancer resistance to radiation and chemotherapeutics treatments
(Bao et al, 2006; Liu et al, 2006). However, unlike normal tissue
stem cells, CSCs may be heterogeneous (Wicha, 2008; Wright et al,
2008; Xu et al, 2008), meaning that all CSCs from tumours of the
same tissue origin and grade, or even from the same tumour, are
not the same. For example, both CD44
þ/CD24
  and CD133
þ cell
populations had been identified from the same cancer in a BRCA
breast cancer model (Wright et al, 2008), suggesting that one initial
mechanism may lead to diverse CSCs with different phenotypes.
This conclusion may explain the paradoxical findings from a
recent study identifying non-CD133
þ cells as colon cancer-
initiating cells (Shmelkov et al, 2008), as opposed to results from
two other studies (O’Brien et al, 2007; Ricci-Vitiani et al, 2007). As
another example, we have identified both hedgehog signalling-
dependent and -independent CSCs from human glioblastomas (Xu
et al, 2008). For these hedgehog signalling-dependent CSCs,
suppression of hedgehog signalling inhibited CSC self-renewal
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Figure 5 Pituitary adenoma stem-like cells can initiate transplantable, hormone-positive brain tumours. (A) Immunofluorescence staining of brain sections
from mice implanted with somatotroph pituitary adenoma-derived PASC1 for 3–6 months using antibodies against human-specific nuclei and human GH.
Two different samples of 6 months (a and b) were shown with similar results. Human-specific antibody stained cells were visualised by FITC-conjugated
secondary antibody (green). The human GH-positive cells were identified by Texas Red-conjugated secondary antibody (red). DAPI was used to identify
nuclei (blue). The overlay images were showed as well. (B) Histological staining of mouse brain sections at 6 weeks after PASC1 implantation: (a)
hematoxylin and eosin; (b) human GH; (c) human PRL; and (d) Ki67 staining. Scale bar, 10mm. (C) Forebrains around the implantation site from the mice at
3 months were harvested under a dissection microscope. The dissected samples were homogenised. A human GH-specific ELISA kit was used to detect the
human GH levels in the tissue extract. Tumours derived from glioblastoma (U87) cells were used as control.
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sand CSC-initiated brain tumour growth. Hedgehog signalling
activity in PTEN-expressing glioblastomas was negatively asso-
ciated with survival time of the cancer patients. This recent study
suggested, on the other hand, that CSCs from different glioblas-
tomas are not equivalent in their underling genetic programs,
signalling pathways, and resultant cancer progression, prognosis,
and responses to signalling-specific targeted treatments. The
qualitative difference among CSCs implies that the mere existence
or quantity of CSCs in a tumour may not be a predictor of
malignancy or tumour progression. Our current study of isolation
of tumour stem-like cells from benign tumours, although generally
supporting cancer stem cell hypothesis, further reinforced the
postulation that tumour stem-like cells are not associated with
malignancy.
Our study is one of the first to isolate and phenotypically and
functionally characterise pituitary adenoma stem-like cells. Line-
age analysis and transcriptional control studies in developing
pituitary gland generated knowledge about pituitary tissue stem
cells and their functions (Zhu and Rosenfeld, 2004; Lee et al, 2005;
Virard et al, 2006; Zhu et al, 2006). Vankelecom and colleagues
isolated murine pituitary cells from side populations that can be
clonally expanded and share many stem cell characteristics (Chen
et al, 2005; Krylyshkina et al, 2005; Vankelecom, 2007). Other
laboratories also identified pituitary colony-forming cells and their
multipotent differentiation capabilities (Lepore et al, 2005, 2006;
Mogi et al, 2005). Although propagating cells or cell lines that
share certain stem-like cell markers had been isolated from
pituitary tumours (Danila et al, 2000; Horvath and Kovacs, 2002;
Abbud et al, 2005), stringent functional characterisation of
pituitary tumour stem-like cells has been scarce. In this study,
we phenotypically and functionally characterised PASCs from both
hormone-positive and -negative pituitary adenomas. We demon-
strated that these PASCs were capable of self-renewal and
multipotent differentiation in vitro and initiation of serially
transplantable pituitary tumours in vivo. Importantly, only PASCs
from GH-positive somatotroph tumours can initiate tumours that
are also GH-positive. Our study conclusively demonstrated the
existence of stem-like cells in benign tumours.
Most recently, there has been evidence suggesting that tumour
stem-like cells may not be so rare and that the concept may not
apply to all types of cancers. It has been shown that a high
frequency (10% or higher) of certain lymphomas and leukaemia
may initiate new cancers (Kelly et al, 2007). Although this finding
is interesting, its implications remain unclear as it is based on
experimentally engineered murine tumours. In another recent
report, Morrison and colleagues discovered that the frequency of
melanoma cancer-initiating cells may be as high as one quarter, as
long as completely immune deficient mice (NOD/SCID/IL2Rg-null
mice), instead of widely used NK cell-containing NOD/SCID mice,
were used as recipient mice (Quintana et al, 2008). It is possible
that the cancer stem cell theory may not apply to all types of
cancer, such as melanomas. In reality, human cancers develop and
progress in patients who possess immune systems of various
functionality. To what degree the murine models apply to human
cancers remains an open question.
Clearly, more investigations are warranted to further understand
the molecular aspects of these PASCs. For instance, what, if any, are
the specific molecular markers that distinct PASCs from non-tumour-
initiating cells? What molecular mechanisms underlie the self-renewal
of PASCs? Is there any relationship between PASCs and pituitary stem
cells? What are the defining differences between stem-like cells from
benign tumours and from malignant tumours? Future studies in this
area will help answer these questions and bring us more knowledge
about tumour stem-like cells in most cancers.
In summary, we have isolated self-renewable and multipotent
stem-like cells from various pituitary adenomas. We demonstrated
that these pituitary tumour stem-like cells, when implanted into
immune compromised mice, can initiate transplantable pituitary
tumours that resemble the primary tumours. This study for the
first time indicated that stem-like cells are present in benign
tumours. The conclusions from this study may have applications
to understanding pituitary tumours, as well as implications in
cancer stem cell theory in general.
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